Population pharmacokinetics and dose optimization of vancomycin in neonates

• Published in: Scientific reports 2021-03, Vol.11 (1), p.6168-8, Article 6168
• Main Authors: Lee, Soon Min, Yang, Seungwon, Kang, Soyoung, Chang, Min Jung
• Format: Article
• Language: English
• Subjects: 631/114; 692/308; 692/699; Antibiotics; Body weight; Creatinine; Dosage; Electronic medical records; Humanities and Social Sciences; Isometric; Monte Carlo simulation; multidisciplinary; Neonates; Pharmacokinetics; Population; Science; Science (multidisciplinary); Therapeutic drug monitoring; Vancomycin
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-85529-3

The pharmacokinetics of vancomycin vary among neonates, and we aimed to conduct population pharmacokinetic analysis to determine the optimal dosage of vancomycin in Korean neonates. From a retrospective chart review, neonates treated with vancomycin from 2008 to 2017 in a neonatal intensive care unit (NICU) were included. Vancomycin concentrations were collected based on therapeutic drug monitoring, and other patient characteristics were gathered through electronic medical records. We applied nonlinear mixed-effect modeling to build the population pharmacokinetic model. One- and two-compartment models with first-order elimination were evaluated as potential structural pharmacokinetic models. Allometric and isometric scaling was applied to standardize pharmacokinetic parameters for clearance and volume of distribution, respectively, using fixed powers (0.75 and 1, respectively, for clearance and volume). The predictive performance of the final model was developed, and dosing strategies were explored using Monte Carlo simulations with AUC 0–24 targets 400–600. The patient cohort included 207 neonates, and 900 vancomycin concentrations were analyzed. Only 37.4% of the analyzed concentrations were within trough concentrations 5–15 µg/mL. A one-compartment model with first-order elimination best described the vancomycin pharmacokinetics in neonates. Postmenstrual age (PMA) and creatinine clearance (CLcr) affected the clearance of vancomycin, and model evaluation confirmed the robustness of the final model. Population pharmacokinetic modeling and dose optimization of vancomycin in Korean neonates showed that vancomycin clearance was related to PMA and CLcr, as well as body weight. A higher dosage regimen than the typical recommendation is suggested.